印度禁止间接推广肥胖药物,以防止误导性主张和保护公共健康。 India bans indirect promotion of obesity drugs to prevent misleading claims and protect public health.

印度的药物监管者CDSCO发布了一项严格的建议,禁止制药公司通过疾病意识运动、社交媒体或影响力营销间接推广处方肥胖药物,如GLP-1受体激动剂。 India’s drug regulator, CDSCO, has issued a strict advisory banning pharmaceutical companies from indirectly promoting prescription obesity drugs like GLP-1 receptor agonists through disease awareness campaigns, social media, or influencer marketing. 这项行动于2026年3月11日生效, 禁止一切夸大重量损失结果、许诺有保证的结果、或低估饮食和运动需要的公共宣传活动。 The move, effective March 11, 2026, prohibits all public-facing promotional activities that exaggerate weight-loss results, promise guaranteed outcomes, or downplay the need for diet and exercise. 公司必须确保这些药物只由注册医生按照核准的用途开具,并保持准确的开具信息、申诉机制和风险管理计划。 Companies must ensure these drugs are only prescribed by registered doctors according to approved uses and maintain accurate prescribing info, grievance mechanisms, and risk management plans. 该指令旨在防止误导性营销,并在对减重药品的需求不断增长的情况下保护公众健康。 The directive aims to prevent misleading marketing and protect public health amid rising demand for weight-loss medications.